Credit Suisse analyst Martin Auster upgraded Solid Biosciences (NASDAQ: SLDB) from Underperform to Neutral with a price target of $7.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE